Movement Alert｜AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback

Market Focus07-28

On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.

On the news front, the company announced on July 26 that it granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share, alongside 1,648,500 restricted share units to 162 grantees under its equity incentive plans. The current stock price has fallen below the exercise price, amplifying short-term market sentiment around potential dilution. The stock had rallied nearly 6% on July 23 following positive OS data updates from its global Phase III HARMONi study for ivonescimab, but has since pulled back for three consecutive trading days.

Within the Biotechnology sector, the overall sector was broadly weak. Among individual stocks, LEADS BIOLABS-B down 4.22%, KEYMED BIO-B down 4.31%, BEIGENE down 1.65%, INNOVENT BIO down 1.12%, 3SBIO down 1.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194999188?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194999188","market":"us","top_or_hot":-1,"title":"Movement Alert｜AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback","media":"Market Focus","content":"<p><p>On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.</p><p>On the news front, the company announced on July 26 that it granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share, alongside 1,648,500 restricted share units to 162 grantees under its equity incentive plans. The current stock price has fallen below the exercise price, amplifying short-term market sentiment around potential dilution. The stock had rallied nearly 6% on July 23 following positive OS data updates from its global Phase III HARMONi study for ivonescimab, but has since pulled back for three consecutive trading days.</p><p>Within the Biotechnology sector, the overall sector was broadly weak. Among individual stocks, LEADS BIOLABS-B down 4.22%, KEYMED BIO-B down 4.31%, BEIGENE down 1.65%, INNOVENT BIO down 1.12%, 3SBIO down 1.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Falls 3.04% in Regular Trading, Share Option Grant Sparks Dilution Concerns Amid Biotech Sector Pullback\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-28 10:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.</p><p>On the news front, the company announced on July 26 that it granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share, alongside 1,648,500 restricted share units to 162 grantees under its equity incentive plans. The current stock price has fallen below the exercise price, amplifying short-term market sentiment around potential dilution. The stock had rallied nearly 6% on July 23 following positive OS data updates from its global Phase III HARMONi study for ivonescimab, but has since pulled back for three consecutive trading days.</p><p>Within the Biotechnology sector, the overall sector was broadly weak. Among individual stocks, LEADS BIOLABS-B down 4.22%, KEYMED BIO-B down 4.31%, BEIGENE down 1.65%, INNOVENT BIO down 1.12%, 3SBIO down 1.05%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1194999188","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194999188","pubTimestamp":1785206827,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.On the news front, the company announced on July 26 that it granted 3,603,500 share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO 常规交易中下跌 3.04%，生物技术板块回调中股票期权授予引发稀释担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On July 28, AKESO declined 3.04% in regular trading, trading at HK$95.75/share, with turnover of HK$183 million.On the news front, the company announced on July 26 that it granted 3,603,500 share options to 167 grantees at an exercise price of HK$99.50 per share, alongside 1,648,500 restricted share units to 162 grantees under its equity incentive plans. The current stock price has fallen below the exercise price, amplifying short-term market sentiment around potential dilution. The stock had rallied nearly 6% on July 23 following positive OS data updates from its global Phase III HARMONi study for ivonescimab, but has since pulled back for three consecutive trading days.Within the Biotechnology sector, the overall sector was broadly weak. Among individual stocks, LEADS BIOLABS-B down 4.22%, KEYMED BIO-B down 4.31%, BEIGENE down 1.65%, INNOVENT BIO down 1.12%, 3SBIO down 1.05%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194999188","isCrawlerRequest":true}